624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials

229 ASH denotes this abstract as clinically relevant

Locke J. Bryan, Carla Casulo,  Pamela Allen, et al.

Pembrolizumab plus ICE chemotherapy leads to a high CMR rate (assessed by PET / CT). The regime is well tolerated. After the transplant, the patients had excellent PFS and OS. 



Veronika Bachanova, Livia Hegerova, Qing Cao, et al.

Patients with R / R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: ruxolitinib plus nivolumab leads to encouragingly high remission rates and sustained responses. The therapy is well tolerated.


231 ASH denotes this abstract as clinically relevant

Pamela Allen, Qing C Chen, Xinyan Lu, et al.

The sequential pembrolizumab and AVD chemotherapy remain a highly effective strategy after prolonged observation:  High response rates were observed for all PD-L1 / PD-L2 levels and 100 percent of the patients remained alive without relapse, suggesting that response to PD-1 blockade in previously untreated cHL may occur even in low levels of PD-L expression.


232 ASH denotes this abstract as clinically relevant

Julien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.

The results in elderly, frail patients with cHL suggest that nivolumab-based therapy is active in a subgroup of patients in this setting.


233 ASH denotes this abstract as clinically relevant

Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, et al.

The results of treatment with pembrolizumab + AVD without PD-1 lead-in show: This is a safe and effective therapy for Frontline HL. PET2 + following APVD does not seem to have a high risk of disease relapse.



Alex F. Herrera, Lu Chen, L. Elizabeth Budde, et al.

Pembrolizumab and vorinostat led to a high ORR and CR rate in patients with anti-PD1 naive/sensitive RR-HL. The combination was tolerated and most patients with anti-PD1 refractory RR-HL had an objective response. This also applies to patients who progressed during prior PD1 blockade.